CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a ...
The Institute of Medicine’s Forum on Neuroscience and Nervous System Disorders planned and held a public workshop June 16, 2009, that brought together experts from industry, academia, government, and ...
Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB) Patients were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results